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1. Introduction
Proteinoids, polymers made of amino acids by thermal condensation polymerization, are
unique synthetic polymers studied by Fox and coworkers [1-7]. When present in certain
concentrations in aqueous solutions, the proteinoids form small microscopic structures called
“proteinoid microspheres” or protocells [4]. The proteinoid, made of most common amino
acids, goes through a self-assembly process in specific conditions, as some of the amino acids
incorporated into proteinoid chains are more hydrophobic than others, thus proteinoids
cluster together like droplets of oil in water [5-7].
The amino acids, either natural or synthetic, are polymerized by step-growth polymerization
in a special procedure discovered by Fox and Harada [8-12]. The procedure involves heating
amino acids until they melt at first, and then the polymerization is initiated to give the
proteinoid. The polymerization takes place at a relatively high temperature (e.g., 180 °C), in
absence of a solvent or a catalyst, and in an inert atmosphere. The accepted explanation of this
polymerization process is that glutamic acid is used as a solvent for the other monomers, as it
is condensed into pyroglutamic acid. The pyroglutamic acid initiates the polymerization with
the rest of the present amino acids [11-14]. A brief description of the polymerization process
is shown in Figure 1.
An important advantage in using biodegradable polymers bearing one or more stereogen‐
ic centers- optically active polymers- is the high variety of features they offer, when used
as carriers for drug delivery systems [15]. This study is intended to broaden the scope of
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biodegradable  polymers  by  synthesizing  new  proteinoids  carrying  various  stereogenic
centers. The main goal is to provide a large choice of biodegradable proteinoids with pre-
determined characteristics,  while  using amino acids  as  building blocks.  Hence,  the  new
selection is based on chiral building blocks carrying positive/negative charge, hydrophilic/
hydrophobic nature or any desired combination of the above [16]. Homopolymers, random
copolymers  and  block-copolymers  of  two  amino  acids  or  more  can  be  designed  and
synthesized, presenting thereby new proteinoid materials with specific, desired nature. The
large variety of amino acids, either natural or synthetic, makes it possible to obtain a large
library of  different  proteinoids,  by  simply changing the  amino acids  ratios.  One protei‐
noid is completely different from another, by the fact that they are made of different amino
acid monomers. This fact provides each proteinoid special features, and possibly influen‐
ces the character of particles made from it [17-20].
Up until now, most, if not all, of the reported proteinoids in the literature were synthesized
from at least four amino acids and possessed relatively low molecular weights [21,22]. Thus,
high molecular weight proteinoids of narrow size distribution made of two to three natural
amino acids, along with proteinoids containing poly(L-lactic acid) (PLLA) segments are
presented in this study. Furthermore, the study presents NIR fluorescent proteinoid-based
particles, which can be used for colon cancer detection. Some of the methods used have been
published in a previous work [23].
2. Incorporation of poly(L-lactic acid) into the proteinoid backbone
Poly(lactic acid) or PLA is the thermoplastic aliphatic polyester of lactic acid, derived from
renewable sources. It is the one of the most important bioplastics in the world in terms of
Figure 1. Thermal polymerization of amino acids through pyroglutamic acid catalysis.
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consumption volume. PLA can be processed by extrusion, injection molding, film and sheet
casting, and spinning, providing access to a wide range of materials and applications. Two
racemic structures of PLA, the L form and the D form, are known as PLLA and PDLA,
respectively [24].
PLA is already used in many biomedical applications, as it is able to degrade into innocuous
lactic acid and is very safe [25-29]. Medical implants made of PLA and approved by the FDA
are anchors, screws, plates, pins, rods, and as a mesh. Depending on the specific type used,
the implants degrade inside the body within 6 to 24 months. The strength characteristics of
PLA and PLLA implants is well documented [30,31].
PLA can also be used as a compostable packaging material, either cast, injection molded,
or spun. Also, cups, bags, hygene products and diapers have been made from PLA [32].
3. Proteinoid microspheres
After preparation, the crude proteinoids can self-assemble to form micro- and nano-sized
particles [33, 34]. As opposed to polystyrene microparticles, for example, which are formed
during  the  polymerization  process  of  styrene  in  the  presence  of  a  surfactant  [35],  the
proteinoid particles are formed through a self-assembly process. This process is complet‐
ed only after the polymerization itself. The procedure involves either dissolving the dried
crude proteinoid in water by heating and then cooling slowly,[36] or by pH changes of the
proteinoid solution in water [37]. This way, particles of the size range of several nanome‐
ters to 10 µm may be formed [38].
The idea standing behind the unique self-assembly process lies in the existence of many
functional groups as a part of the random polymer backbone. The preparation of proteinoid
microspheres does not require the addition of any toxic cross-linking agents or surfactants.
The conversion of the polypeptidic proteinoid solution into particles with a slight change of
the environment involves a complex process of functional group changes occurring in the
polymer. The great amount of carboxylates in the backbone, or aminium ions when dealing
with a lysine-rich proteinoid, cause the solubility of the proteinoid in certain conditions and
insolubility in the reverse conditions [39]. The hydrophobic portions of the proteinoid are
assembled within the particle matrix, and the carboxylic acid moieties are exposed, as
illustrated in Figure 2 [40].
When the self-assembly procedure is done in the presence of a suitable molecule such as drug
or dye, a proteinoid particle containing the molecule is formed [41]. The proteinoids may be
used to encapsulate materials such as drugs for drug delivery purposes, e.g. for the oral
delivery of methotrexate [40], Hydroxyapetite [42], Cholesterol [37] and for diagnostics
[21,43-48].
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4. Preparation of proteinoids by thermal condensation polymerization
L-glutamic acid was heated to the molten state (180°C) in an oil bath, under nitrogen atmos‐
phere. The molten mass was stirred at 180°C for 30 min. To this, different contents of additional
L-amino acids were added to give a total monomer weight of 5-5.01 g, as specified in Table 1,
and kept at 180°C under nitrogen. The mixture was mechanically stirred at 150 rpm for 3 h.
The product is a highly viscous orange-brown paste, which hardens to give a glassy mass when
cooled to room temperature. Then, water (10 mL) was added to the crude product, and the
mixture was stirred for 20 min. The solution was then intensively dialyzed through a cellulose
membrane (3500 Da MWCO) against distilled water. The content of the dialysis tube was then
lyophilized to obtain a yellow-white proteinoid powder.
Polymer Amino acid content (g)a
L-Glu L-Asp L-Lys L-Phe PLLA
Prot1 5 - - - -
Prot2 2.5 2.5 - - -
Prot3 2.5 - - 2.5 -
Prot4 1.25 2.5 - 1.25 -
Prot5 1.67 1.67 1.67 - -
Prot6 1.67 - 1.67 1.67 -
Prot7 1.25 - 2.5 1.25 -
Prot8 2.25 - - 2.25 0.5
Table 1. Amino acid content of the different proteinoids. aIn all proteinoids made by thermal condensation
polymerization the total monomer content was 5-5.01 g; bmade by microwave-assisted polymerization.
4.1. Polymerization kinetics study at different temperatures
Polymerization  kinetics  was  studied  by  collecting  proteinoid  samples  from the  reaction
vessel at different time periods of the polymerization at 180, 190 and 200°C. The samples
Figure 2. Schematic representation of the self-assembled proteinoid particles. Hydrophobic moieties are represented
by scribbled lines. When lysine is also a part of the proteinoid, as in Prot5-7, some carboxyl groups are exchanged with
amine groups.
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were then analyzed by both ninhydrin test  for  the  determination of  the  primary amine
groups content and Biuret test for the determination of the amide groups content of the
various  proteinoids  [49].  The  results  shown in  Figure  3  refer  to  the  synthesis  of  Prot3,
consisting of L-glutamic acid and L-phenylalanine. Similar results were observed for the
other systems, Prot1-8, as well. It can be seen that at all temperatures, the polymerization
takes place mainly over the first 100 min. After that, both ninhydrin (A) and Biuret (B) tests
show no significant drop of the Ninhydrin signal indicating the amount of free amines or
rise of the peptide bonds shown by the Biuret signal. This figure also shows that as the
temperature of  the reaction was raised,  the rate of  the reaction increased.  However,  the
preferred reaction temperature  is  180°C,  as  the  yield of  the  reaction is  higher  since  the
amino acids decompose faster at the higher temperatures.
Figure 3. Thermal polycondensation kinetics of (L)glutamic acid and (L)phenylalanine to yield Prot3 at different tem‐
peratures by two tests: ninhydrin test (A) and Biuret test (B).
5. Proteinoid analysis and characterization
The molecular weights and polydispersity index of the dried crude proteinoids were deter‐
mined using Gel Permeation Chromatography (GPC) consisting of a Waters Spectra Series
P100 isocratic HPLC pump with an ERMA ERC-7510 refractive index detector and a Rheodyne
(Coatati, CA) injection valve with a 20 µL loop (Waters, MA). The samples were eluted with
super-pure HPLC water through a linear BioSep SEC-s3000 column (Phenomenex) at a flow
rate of 1 mL/min. The molecular weights were determined relative to poly(ethylene glycol)
standards (Polymer Standards Service-USA, Silver Spring, MD) with a molecular weight range
of 100-450000 Da, using Clarity chromatography software. The optical activities of the
proteinoids were determined using a PE 343 polarimeter (PerkinElmer). All of the measure‐
ments were done in water, at 589 nm at 25°C. Table 2 shows the characteristic molecular
weights, polydispersity and optical activity of the prepared proteinoids.











Prot1 26250 11300 11320 2.32 +6.5
Prot2 181540 144940 195300 1.25 -4.4
Prot2e 500240 497280 503070 1.01 +8.1
Prot3 164930 138250 158740 1.19 -9.0
Prot4 87660 84410 85250 1.04 -3.3
Prot5 195080 165870 191440 1.17 -7.4
Prot6 190390 163290 204050 1.16 -15.1
Prot7 72260 56880 42870 1.27 +2.8
Prot8 168300 156600 136800 1.07 -4.6
Table 2. Mw, Mn, Mp, PDI and optical activity of the various proteinoids.aThe proteinoids were prepared at 180°C
according to section 3.2.1; bmolecular masses were measured by GPC, Mp is the molecular mass at the peak; cPDI is the
polydispersity index, given by Mw/Mn; dspecific optical rotation (c=1, in H2O, at 25°C); emade by microwave-assisted
polymerization.
Table 2 indicates relatively low PDI values for the obtained proteinoids. This is unexpected
since the polycondensation of the various amino acids is random and step-growth polymeri‐
zation processes, as in the present case, result usually in very broad size distribution polymers
[50]. The highest PDI (2.32) was observed for Prot1, composed of the single amino acid L-
glutamic acid, while the PDIs of the other proteinoids composed of at least 2 amino acids were
ranging between 1.01 and 1.27. All of the thermally-made proteinoids have relatively high
molecular masses of 26-195 kDa. This indicates that the polymerization procedure by thermal
heating used here provides relatively long polymer chains. This fact may serve as an advantage
for different uses later, since polymers with such high molecular weights are usually mechan‐
ically stronger and resemble natural proteins. Table 2 indicates that the lowest molecular
weight was observed for the proteinoid composed of the single amino acid L-glutamic acid
(Prot1) and the highest one for the proteinoid composed of L-glutamic acid, L-aspartic acid
and L-lysine (Prot 5). Prot2, which was synthesized by microwave-assisted polymerization,
reached an abundantly higher molecular weight. In this procedure, a 500 kDa proteinoid chain
was prepared, about twice the size of the regular thermal proteinoid. This kind of procedure
gives better yield over 60 min, compared to the 3 h needed usually. It can be used further for
higher molecular weights and more rigid proteinoids. However, unfortunately, this kind of
proteinoid does not self-assemble into spherically-shaped particles.
As further indicated from Table 2, all of the proteinoids exhibit optical activity, although the
amino acid monomers are known to racemize during the thermal process [51]. This fact can
become a benefit later in the design of a stereospecific drug carrier, for example.
Fourier Transform Infra-Red (FTIR) measurements of the crude proteinoids were done by the
Attenuated Total Reflectance (ATR) technique, using Bruker ALPHA-FTIR QuickSnapTM
sampling module equipped with Platinum ATR diamond module. All proteinoids showed
characteristic peaks of NH stretching at 3360 and 2990 cm-l, amide CO stretching at 1565 cm-1,
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an amide NH bending band at 1450 cm-1 and CO bending at 500-700 cm-1. A representative
spectrum of Prot3 is shown in Figure 4.
Figure 4. FTIR spectrum of Prot3.
The thermal behavior of the proteinoids was determined using Differential Scanning Calo‐
rimetry (DSC) and Thermo Gravimetric Analysis (TGA) with a TGA/DSC 1 STARe system
(Mettler Toledo, Switzerland). The samples were heated between 25 - 400 °C at a rate of 10°C/
min under nitrogen atmosphere. The results are shown in Table 3.
Polymer Tm(°C)a ∆Hm (J/g)a Tdec (°C)b Weight loss (%)
at 400°Cb
Prot1 102 -300.7 300 55
Prot2 89 -428.7 297 57
Prot3 103 -174.9 341 54
Prot4 217 -183.4 330 25
Prot5 78 -251.5 339 57
Prot6 241 -90.1 373 47
Prot7 246 -139.4 385 64
Prot8 117 -420.5 268 47
PLLAc 150 -57.2 349 90
Table 3. Thermal properties of proteinoids produced by thermal polymerization.aTm and ∆Hm were measured by
DSC; bTdec (temperature of decomposition) was measured by TGA/DSC and refer to the exothermal peak in DSC,
ccommercial PLLA 2000 Da parameters were measured similar to the made proteinoids.
The melting temperatures of the different proteinoids range between 78-246°C. The wide range
of temperatures derives from the difference in the monomeric units used in each proteinoid.
When using phenylalanine, as in Prot3, 4, 6 and 7, the resulted proteinoid gains significant
rigidity in the overall structure, due to the aromatic rings which allow pi-stacking. Hence, these
proteinoids melt at higher temperatures. When PLLA is incorporated into the proteinoid, as
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in Prot8 compared to Prot3, the Tm rises mildly (103°C and 117°C, respectively), due to the
presence of 2000 Da rigid polymer chains in the overall proteinoid structure.
The TGA/DSC measurements of the proteinoids show decomposition temperatures of
268-385°C. Most proteinoids lose at this temperature range around 50% of their weight The
decomposition measured at 400°C of most proteinoids is between 47-64%, except Prot4 (25%).
Pure PLLA decomposes at 349°C almost completely (90% weight loss). Prot8, composed of
PLLA segments (10% of the total monomer), has the lowest decomposition temperature of all
proteinoids (268°C). This can be explained by the non-uniformity of the structure of the whole
proteinoid due to the inserted segments of 2000 Da PLLA within the random segments of
polymerized amino acids.
The content of free carboxyl groups in the synthesized proteinoids is an essential factor in
determining their solubility in different media, thus helping to understand their stability at
different sites in the human body with different pHs. In order to determine the free carboxyl
groups in the synthesized proteinoids, a titrimetric method was carried out [40]. Briefly, to a
known quantity of dry proteinoid, a known excess of 0.05 N NaOH was added, followed by
the addition of 37% formaldehyde solution. The unreacted NaOH was back-titrated with
standard 0.05 N HCl. A blank titration was also performed. In addition, human serum albumin
(HSA) was titrated for comparison. Table 6 indicates the carboxyl group contents of the
synthesized proteinoids, showing higher values of 80-155 mmol/g compared with albumin.
This is true also in Prot5-7, where lysine is also a part of the polymer. Moreover, aspartic and
glutamic acid moieties in the proteinoids, along with lysine, impart the hydrophilic nature of
the whole proteinoid. The biodegradability rate of various amino acid polymers increases with
their hydrophilicity [40]. Therefore, it is more appropriate to choose these proteinoids as ideal
biomaterials for drug delivery applications.










Table 4. Carboxyl group content in the proteinoids and albumin.
5.1. Incorporation of poly(L-lactic acid) into the proteinoids
In order to effect the chemical and physical properties of the product, a thermal polymerization
of L-glutamic acid and L-phenylalanine was carried out in the presence of low molecular
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weight poly(L-lactic acid) (PLLA, 2000 Da). The proteinoid-PLLA (Prot8) consists of 2.25 g of
each amino acid and 0.5 g of PLLA. After polymerization, it was washed, dried and charac‐
terized as described earlier. The characterization of Prot8 is included in the tables above.
6. Preparation and characterization of the proteinoid nano/micro-particles
by a self-assembly process
Proteinoid particles were prepared by a self-assembly mechanism. Briefly, 100 mg of the dried
proteinoid were added to 10 mL 10-5N NaCl solution. The mixture was then heated to 80°C
until the crude proteinoid dissolves completely. Proteinoid particles were then formed by
removal of the heating and leaving the mixture to cool to room temperature.
Hydrodynamic diameter and size distribution of the particles dispersed in double distilled
(DD) water were measured at room temperature with a particle DLS analyzer model Nano‐
phox (SympatecGmbH, Germany).
Dried particle size and size distribution were measured with a Scanning Electron Microscope
(SEM). SEM pictures were obtained with a JEOL, JSM-840 Model, Japan. For this purpose, a
drop of dilute particle dispersion in distilled water was spread on a glass surface, and then
dried at room temperature. The dried sample was coated with carbon in vacuum before
viewing under SEM. The average particle size and distribution were determined by the
measurement of the diameter of more than 200 particles with image analysis software
(Analysis Auto, Soft Imaging System GmbH, Germany). Figure 5 exhibits the proteinoid
particles made from self-assembly of Prot8. The procedure produced spherical proteinoid
particles of 103 ± 11 nm hydrodynamic diameter and 70 ± 15 nm dry diameter. The dry diameter
of the proteinoid particles is illustrated by the typical SEM photomicrograph shown in Figure
5A. The hydrodynamic diameter of these particles dispersed in water is illustrated by the
typical light scattering measurement shown in Figure 5B. The difference in the particle size
between the SEM and the light scattering measurements is probably due to the fact that SEM
measurements determine the dry diameter, whereas light scattering measurements take into
account the hydrated water layers adsorbed onto the particle’s surface.
The density of the particles was determined by pycnometry [52]. Briefly, dry pre-weighed
particles were put in a calibrated pycnometer, which was then filled with water. The density
of the sample can then be calculated from the known density of the water, the weight of the
pycnometer filled only with water, the weight of the pycnometer containing both the sample
and water, and the weight of the sample, as described in the literature [52]. Density measure‐
ments indicated that all proteinoid particles possess a very low density, ranging from 0.001 to
0.014 g/mL indicating that the particles formed are probably hollow, as already indicated for
the proteinoids prepared by Fox et al [6,38]. The hollow nature of the particles is significantly
important for applications such as ultrasound imaging agents, drugs and dyes encapsulation,
controlled released, etc.
As suggested in our and in previous studies, the proteinoid forms particles of different sizes
according to the nature of its surrounding. The hydrophobic portions of the crude proteinoid
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are assembled within the particle matrix, while the polar hydrophilic groups (carboxyl and
amines) are exposed to the aqueous environment, as illustrated before in Figure 2 [40].
6.1. Particle stability in storage conditions
Proteinoid particles aqueous dispersions (1 mg/mL) were put in a refrigerator at 4°C for 6
months. Samples were taken at different time periods, filtered through a centrifugation tube
(Vivaspin 3000 Da MWCO) and the filtrate was checked by UV at 200-210 nm, to find aqueous
soluble proteinoid. Also, the particle aqueous dispersions were checked by Nanophox for their
size and size distribution. In order to check the particle stability after drying, the particles were
lyophilized to dryness and then dispersed in an aqueous phase to their original concentration.
The samples size and size distribution were then rechecked by Nanophox. Overall, the
proteinoid particles remain in the same size after 6 months in storage at 4°C. Also, the
degradation and/or dissolution of the proteinoid particles in the aqueous continuous phase
was tested by the filtration centrifugation method and resulted in negative results in the filtrate,
meaning no degradation or dissolution occurs at this temperature over 6 months. When
lyophilized to dryness, the proteinoid particles can be redispersed in water completely while
the particle size and size distribution remain the same. This means that the particles can be
stored as a freeze-dried powder as well, and redispersed when needed, without the need to
add cryoprotectants as mentioned in the literature [53].
6.2. Cytotoxicity of the proteinoid particles
In vitro cytotoxicity of the proteinoid particles was tested by using human colon adenocarci‐
noma LS174T cancer cell line. The tests were done on Prot2, Prot4, Prot5, Prot7 and Prot8. The
Figure 5. Hydrodynamic size histogram (A) and SEM image (B) of Prot8 particles.
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cell line is adherent to the used culture dishes. LS174T cells were grown in MEM that was
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% glutamine and 1%
penicillin/streptomycin. Cells were screened to ensure they remained mycoplasma-free using
Mycoplasma Detection Kit [54]. Cell cytotoxicity was assessed by measuring the release of
cytoplasmic lactate dehydrogenase (LDH) into cell culture supernatants. LDH activity was
assayed using the Cytotoxicity Detection Kit according to the manufacturer's instructions [55].
Cells (3×105 cells per well) were seeded and grown to 90–95% confluency in 24 well plates
before treatment with the proteinoid particles. Cell cultures that were not exposed to the
particles were included in all assays as negative controls. Cell cultures that were treated with
1% Triton-x-100 were used as positive controls. To test if the particles can interact with LDH
kit compounds, cell cultures were exposed to a mixture containing maximal nano/micro-
particles concentration dispersed in PBS and 1% Triton-x-100. The proteinoid particles were
freshly dispersed in PBS (1.25 and 2.5 mg/mL) and then added to the 95% confluent cell culture
in culture medium. The cell cultures were further incubated at 37°C in a humidified 5% CO2
incubator and then checked for cellular cytotoxicity at intervals of 24h. The percentage of cell
cytotoxicity was calculated using the formula shown in the manufacturer's protocol [55]. All
samples were tested in tetraplicates.
Figure 6. Cytotoxic effect of the proteinoid particles on colon adenocarcinoma LS174T cells measured by the LDH as‐
say. Cells (3×105) were incubated for 24 and 48 h with the proteinoid particles dispersed in PBS (1.25 mg/mL and 2.5
mg/mL) according to section 3.2.5.8. Cells were incubated with Triton-x-100 1% as positive control (100% toxicity). In ad‐
dition, cells were incubated with Triton-x-100 1% and each one of the proteinoids to revoke any interaction. Untreated cells
(negative control) were similarly incubated. Each bar represents mean ± standard deviations of 4 separate samples.
When tested by the LDH quantitative assay, Prot2, 4, 5, 7 and 8 particles dispersed in PBS at
concentrations of 1.25 and 2.5 mg/mL had none, or minor cytotoxic effect on the human colon
adenocarcinoma cell line LS174T (Figure 6). Treatment of the cells with Prot2 and Prot5
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particles at both concentrations produced the highest LDH levels (up to 13% toxicity), when
compared to untreated (blank) cells, indicating minor toxicity of these proteinoids to this cell
line. Prot8 had the lowest cytotoxic effect on the cells treated with both concentrations, almost
zero toxicity. This proteinoid is therefore the most suitable for treating cells, considering its
low toxicity.
7. NIR flourescent proteinoid-PLLA particles
7.1. Synthesis of the NIR fluorescent Prot8 particles
The optimal Prot8 particles were used to encapsulate ICG, a well-known NIR dye already in
use in medical diagnostics. The NIR fluorescent particles were prepared by self-assembly of
the crude Prot8, in the presence of ICG. Briefly, 100 mg of the dried fabricated Prot8 were
resuspended in 10 mL of 10-5N NaCl solution. The mixture was then heated to 80°C while
stirring for 15 min. To this solution, 1 mg (1% of the proteinoid polymer) of ICG was added.
The mixture was then removed from the hot plate and was allowed to return to room tem‐
perature. During the cooling process hollow particles were formed and precipitated from
solution. The obtained NIR fluorescent particles dispersed in water were then dialyzed versus
4 L of 10-5 NaCl aqueous solution overnight at room temperature.
7.2. Determination of the encapsulated ICG concentration in the NIR fluorescent Prot8
particles
A calibration curve of free ICG was obtained by measuring the integrals of absorbance peaks
of standard solutions (0.5–10 µg/mL) in PBS, at wavelengths 630–900 nm. The concentration
of the encapsulated ICG was determined by measuring the integral of the absorbance spectrum
at 630-900 nm of a 1 mg/mL dispersion of the NIR fluorescent particles in PBS. An estimation
of encapsulated ICG per mg of particles was determined according to the calibration curve.
7.3. Characterization of the NIR fluorescent Prot8 particles
Hydrodynamic and dry particle size and size distribution were determined by DLS and SEM,
as mentioned above. For the SEM study, the diameter of more than 200 particles with image
analysis software (AnalySIS Auto, Soft Imaging System GmbH, Germany). The self-assembly
procedure produced spherical proteinoid particles of 145 ± 20 nm hydrodynamic diameter and
70 ± 15 nm dry diameter, as shown in Figure 7. The hydrodynamic diameter of these particles
dispersed in water is illustrated by the typical light scattering measurement shown in Figure
7A. The dry diameter of the proteinoid particles is illustrated by the typical SEM photomicro‐
graph shown in Figure 7B.
In addition, absorbance spectra were obtained using a Cary 100 UV-Visible spectrophotometer
(Agilent Technologies Inc.). Excitation and emission spectra were recorded using a Cary
Eclipse spectrofluorometer (Agilent Technologies Inc.). As indicated in Figure 8, no shift of
absorbance of the ICG after encapsulation is observed compared to that of the free ICG.
Advances in Bioengineering60
However, due to the dye encapsulation process, the maximal absorbance peak of the free ICG
changed from 779 nm to 718 nm, probably since the ICG molecules get close to each other
inside the nanoparticle interior and aggregation of the dye may occur causing this change in
absorption peaks [56,57]. Furthermore, a 12 nm blue-shift of the emission spectrum of the NIR
fluorescent particles compared to the free dye in solution is also observed.
The estimation of encapsulated ICG showed that the complete quantity of ICG used in the
encapsulation procedure was encapsulated within the Prot8 nanoparticle interior. Following
particle formation, leakage of the encapsulated ICG into PBS not-containing and containing
4% albumin at room temperature was not observed, indicating that the dye is strongly
associated within the Prot8 particles, probably due to physical interactions between the dye
and the polymer hydrophobic portions assembled in the core of the particles.
As suggested before, the proteinoid forms particles of different sizes according to the nature
of its surrounding [40]. When discussing Prot8, the hydrophobic portions, in this case mainly
the PLLA segments and the aromatic rings of the phenylalanine portion are assembled within
the particle matrix, while the polar hydrophilic groups (mainly carboxylates) are exposed to
the aqueous environment. This way, the self-assembly yields particles that encapsulate within
them the ICG associated with the hydrophobic core via hydrophobic interaction, as illustrated
in Figure 9.
7.4. Optimization of the ICG concentration entrapped within the Prot8 particles
In order to optimize the particles fluorescence intensity, different concentration (0.5, 1, 2 and
5% w/w relative to Prot8) of ICG were added to the Prot8 hot solution, prior to the formation
of the particles through the self-assembly process, as described above. The NIR fluorescent
Figure 7. Hydrodynamic size histogram (A) and SEM image (B) of the P(EF-PLLA) NIR fluorescent nanoparticles.
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Prot8 particles dispersed in PBS were diluted to 1 mg/mL and their fluorescence intensities
were measured at 809 nm. The encapsulated ICG concentration that gave the maximum
fluorescence intensity of the resultant NIR fluorescent particles was 1% w/w relative to Prot8.
At higher dye concentrations, quenching of the fluorescence was observed, as the dye
molecules encapsulated within the Prot8 nanoparticle are close to each other, resulting in non-
emissive energy transfer between them.
7.5. Photostability of the NIR fluorescent Prot8 particles
In order to examine the photostability of  the encapsulated ICG as opposed to free ICG,
photobleaching experiments were performed for both the encapsulated and the free dye.
For  this  purpose,  an  aqueous  solution  of  ICG  (0.05  M)  in  PBS  was  prepared,  and  the
Figure 8. Absorbance and emission spectra of free ICG (dotted lines) and ICG-encapsulated Prot8 particles (solid lines)
dispersed in water.
Figure 9. Schematic representation of the self-assembled NIR fluorescent particles. Hydrophobic moieties are repre‐
sented by scribbled lines, ICG is represented by the interior green dots.
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fluorescence intensity with λex set  at  780 nm and λem set  at  800 nm was measured.  A
dispersion of  NIR fluorescent  Prot8  particles  in  PBS was  prepared,  and diluted to  give
similar  fluorescence  intensity  to  the  dye  at  the  same  wavelengths.  The  excitation  and
emission slits  were  opened to  20  nm and 5  nm,  respectively.  Each of  the  samples  was
illuminated  continuously  with  a  xenon  lamp,  and  the  fluorescence  intensity  was  meas‐
ured over a period of 20 min by a Cary Eclipse fluorescence spectrophotometer (Agilent
Technologies Inc.). Intensity values were normalized for comparison. Figure 10 illustrates
that  during illumination,  the fluorescence intensity of  the ICG-containing Prot8 particles
remains intact  while that  of  the free ICG decreased significantly.  The photobleaching of
ICG is significantly reduced by the encapsulation within the proteinoid-PLLA particles. The
encapsulation probably protects the free dye from light-inducing factors such as oxygen,
oxidizing or reducing agents,  temperature, exposure time and illumination levels,  which
may reduce the fluorescence intensity irreversibly [58,59].
Figure 10. Photostability of the ICG-containing Prot8 particles (A) and free ICG (B) as function of time. Samples of
ICG-containing Prot8 particles and free ICG were illuminated with a Xenon flash lamp for 20 min, as described above.
7.6. In vitro cytotoxicity of the Prot8 particles
In order to revoke cell toxicity of the NIR Prot8 particles, in vitro cytotoxicity of the particles
was tested by using human colorectal adenocarcinoma LS174t, SW480 and HT29 cell lines. The
cell lines are adherent to the used culture dishes. LS174t cells were grown in Minimum
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Essential Medium (MEM) eagle supplemented with heat-inactivated fetal bovine serum (FBS,
10%), penicillin (100 IU/mL), streptomycin (100 µg/mL) and L-glutamine (2 mM). SW480 cells
were maintained in Dulbecco's MEM supplemented with heat-inactivated fetal bovine serum
(FBS, 10%), penicillin (100 IU/mL), streptomycin (100 µg/mL) and L-glutamine (2 mM). HT29
cells were maintained in McCoy's 5A medium supplemented with FBS (10%), penicillin (100
IU/mL), streptomycin (100 µg/mL) and L-glutamine (2 mM). Cells were screened to ensure
they remained mycoplasma-free using Mycoplasma Detection Kit [54]. Cell cytotoxicity was
assessed by measuring the release of cytoplasmic lactate dehydrogenase (LDH) as described
above.
Figure 11 exhibits the cytotoxicity levels of the Prot8 particles at two different concentrations
(1.25 and 2.5 mg/mL). It can be seen that at both concentrations, the Prot8 particles have no
significant cytotoxic effect on all three cell lines, compared to untreated (blank) cells, meaning
that the particles may be used for biomedical applications as suggested, including drug
delivery.
Figure 11. Cytotoxic effect of the NIR fluorescent Prot8 particles on human colorectal adenocarcinoma LS174t, SW480
and HT29 cell lines measured by the LDH assay. Cells (3×105) were incubated for 24 and 48 h with the Prot8 particles
(1.25 and 2.5 mg/mL in PBS). Cells were incubated with 1% Triton-x-100 as positive control (100% toxicity). In addition,
cells were incubated with Triton-x-100 1% and the Prot8 particles (2.5 mg/mL) to revoke any interaction of the particles
with the LDH kit components. Untreated cells (negative control) were similarly incubated. Each bar represents mean ±
standard deviations of 4 separate samples (originally published in [23]).
7.7. In vivo biodistribution in a mouse model
In order to examine the biodistribution in a living body, the NIR fluorescent Prot8 particles (2
mg/mL, 0.01 mg/kg body weight per mouse) were injected i.v. into mice through the tail vein
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and checked at several time intervals over 24 h. Male BALB/C mice (Harlan Laboratories,
Israel) were utilized in this study under a protocol approved by the Institutional Animal Care
and Use Committee at Bar-Ilan University. The biodistribution of the NIR fluorescent Prot8
particles was studied in normal 8-weeks-old mice, weighing 20-25 g at the time of experiment.
Prior to the experiment, mice were anesthetized by intraperitoneal injection of Ketamine (40-80
mg/kg body weight) and Xylazine (5-10 mg/kg body weight), and the mice’s skin was shaved
with an electric animal clipper.
100 µL of either nanoparticle dispersion or free ICG solution (0.01 mg/kg body weight,
dissolved in PBS) were administered to the mice through tail vein injection at a concentration
of 2 mg/mL. During image acquisition, mice remained anesthetized by the intraperitoneal
injection of Ketamine/Xylazine. Image cubes were obtained from the mice at several time
points up to 24 h after injection. Each treatment group includes 3 mice for each time point (5
min, 20 min, 1 h and 24 h); 2 uninjected mice served as negative control. The experiment was
repeated twice, testing a total of 52 mice. At the end of the experiment, the mice were euthan‐
ized by cervical dislocation, and organs were taken for imaging (liver, spleen, kidney, duode‐
num, colon, brain, heart, tibia bone and blood).
Whole body fluorescence images were acquired using a Maestro II in vivo fluorescence
imaging system (Cambridge Research &Instrumentation, Inc., Woburn, MA). The system is
equipped with a fiber-delivered 300W xenon excitation lamp, and images can be acquired from
λ=500-950 nm by a 1.3 megapixel CCD camera (Sony ICX285 CCD chip). Each pixel within the
image cube therefore has an associated fluorescence spectrum. The software for the Maestro
system (Maestro 2.10.0) contains several algorithms to process the spectral data cubes to
remove undesired auto-fluorescence signal and generate overlaid images for multiple
fluorophores. A deep red excitation/emission filter set was used for our experiments (λex:
700-770 nm, λem>780 nm). The liquid crystal tunable filter (LCTF) was programmed to acquire
image cubes from λ=780 nm-860 nm with an increment of 10 nm per image. The camera was
set to 150 ms (whole body image), 15 ms (liver), 500ms (spleen), 7000ms (kidney), 10 ms
(duodenum), 500 ms (colon), 1000ms (brain), 1000ms (tibia bones), 200ms (heart) and 1000ms
(blood) exposure times. Fluorescence intensity measurements were performed using ImageJ
NIH (National Institutes of Health) software.
Figure 12 shows whole body images of mice injected with the particles over time: at 5 min, 20
min, 1 h and 24 h from injection. 5 min post injection, there is an initial burst of fluorescence
which subsided quickly, while the majority of the fluorescent particles concentrated in the
liver, at 20 min. 24 h post injection, the fluorescence is almost non-existent, signifying the
nanoparticle clearance from the body over 24 h. Biodistribution was tested for free ICG as well,
and no significant differences in distribution and kinetics were found between particles
containing ICG and free ICG up to 24 h post injection. These findings were in complete
agreement with previous reports of ICG and ICG-containing particles pharmacokinetics and
biodistribution, as the free dye in solution, derivatives of the free dye and ICG-containing
particles are all evacuated from the body after 1 h and completely vanished 24 h after i.v.
injection [60,61].
Engineering of Novel Proteinoids and PLLA-Proteinoid Polymers of Narrow Size Distribution and…
http://dx.doi.org/10.5772/59626
65
Figure 12. Typical whole body fluorescence images of the NIR fluorescent Prot8 particles at 5 min, 20 min, 1 h and 24 h
after i.v injection. 12 mice (each experiment group contained 3 mice) were anesthetized and treated with NIR fluores‐
cent Prot8 particles (2 mg/mL, 0.01 mg/kg body weight per mouse). Blood was drawn and organs were harvested at
each time point. 2 uninjected mice served as negative control. 12 mice were injected correspondingly with free ICG
solution, giving similar results (not shown). The experiment was repeated twice with similar results (originally pub‐
lished in [23]).
Figure 13. Fluorescence intensities of different organs taken at 5 min, 20 min, 1 h and 24 h post i.v. injection into mice
tail veins. 12 mice (each experiment group contained 3 mice) were anesthetized and treated with NIR fluorescent Prot8
particles (2 mg/mL, 0.01 mg/kg body weight per mouse). Blood was drawn and organs were harvested at each time
point. 2 uninjected mice served as negative control. The experiment was repeated twice with similar results (originally
published in [23]).
Ex vivo fluorescence images of specific organs and blood were also obtained. Organs from mice
were harvested and blood was drawn 5 min, 20 min, 1 h and 24 h post injection of the particles
into the tail vein. Figure 13 shows the calculated fluorescence intensities of the lungs, bones,
brain, colon, duodenum, heart, liver, kidney, spleen and blood screening. Evidently, this
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analysis shows that the particles penetrated and were found in all checked organs. It is shown
clearly that by 20 min most of the inserted quantity of the fluorescent particles is cleared from
the blood. The particles concentrate mostly at the liver and are probably evacuated from the
body. Interestingly, it is also apparent that the particles pass the blood-brain barrier (BBB),
since they are found in the brain at 20 min post injection. This may open up a scope of drug
targeting to the brain for drug molecules which are usually blocked. Overall, it was demon‐
strated that following a single i.v. injection of the particles, fluorescence intensity at all organs
decreased over time, and only traces of fluorescence could be seen after 24 h.
7.8. Conjugation of the tumor-targeting ligands to the particles
PNA was covalently conjugated to the NIR fluorescent Prot8 particles by the cabodiimide
activation method [62]. Briefly, EDC (1 mg) and Sulfo-NHS (1 mg) were each dissolved in 0.1
M MES (pH 6.0, 1 mL) containing 0.5 M NaCl. The EDC solution (1 mg/mL, 10 µL) was added
to an aqueous solution of PNA (0.25 mg, 62.5 µL), followed by the addition of the sulfo-NHS
solution (1 mg/mL, 25 µL). The mixture was then shaken for 15 min, followed by the addition
of the NIR fluorescent Prot8 particles (2.5 mg in 1 mL PBS). The mixture was then shaken for
90 min. The obtained PNA-conjugated fluorescent particles were then washed from excess
reagents by dilution and filtration through a 30-kDa filtration tube (VS2021 VIVA SPIN) at
1000 rpm (Centrifuge CN-2200 MRC) for 2 min, repeated three times. FITC–PNA, anti-CEA
and anti-rabbit IgG were conjugated to the NIR fluorescent particles through a similar
procedure. The concentration of bound PNA was determined with FITC–PNA by a calibration
curve of FITC–PNA fluorescence using a multiplate reader (TECAN SpectraFluor Plus, Neotec
Scientific Instruments). The concentrations of bound anti-CEA and anti-rabbit IgG were
determined using a mouse IgG ELISA kit (Biotest, Israel). The calculated quantities of bound
PNA and anti-CEA were 3.2 and 1.9 µg per mg particles, respectively.
7.9. Optical detection of human colon tumors in a chicken embryo model
7.9.1. The chicken embryo CAM model
A chicken embryo CAM model was used to test the specific tumor detection by both the non-
conjugated and the bioactive (PNA, anti-CEA or anti-rabbit IgG) conjugated NIR fluorescent
Prot8 particles. Among most commonly used animal models, the chicken egg model allows
the imaging of several tumors in a short time period and is less expensive [62]. Tumor cells
were grafted on CAM according to the literature [62,64]. Briefly, fertile chicken eggs obtained
from a commercial supplier were incubated at 37°C at 60–70% humidity in a forced-draft
incubator. On day 3 of incubation, an artificial air sac was formed, allowing the CAM to drop.
After 8 days of incubation, a window was opened in the shell and the CAM was exposed.
Tumor cells were collected by trypsinization, washed with culture medium and pelleted by
gentle centrifugation. Following removal of the medium, 5x106 cells were resuspended in 30
µL ice-cold Matrigel and inoculated on the CAM at the site of the blood vessels. Eggs were
then sealed and returned to incubation. On day 6 post-grafting, day 14 of incubation, the tumor
diameter ranged from 3 to 5 mm with visible neoangiogenesis.
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Figure 14 shows typical SW480 cell line derived tumors bordered by plastic rings on a chicken
embryo CAM inside the egg.
Figure 14. Light photograph of SW480 cell line derived tumors bordered by a plastic ring on chicken embryo CAM.
Suspensions of 5×106 SW480 cells suspended in Matrigel formed compact structures (asterisk) 8 days after transplanta‐
tion with attraction of host blood vessels (arrow).
7.9.2. CAM tumor detection
Chicken embryos with 6-days-old human adenocarcinoma tumors (LS174t and SW480 cancer
cell lines) implanted on the CAM were treated with the non-conjugated, PNA-conjugated and
anti-CEA-conjugated NIR fluorescent Prot8 particles (40 µL, 2 mg/mL). Additionally, non-
pathological CAM treated with non-conjugated particles and untreated tumors served as
control groups. After 40 minutes, the nanoparticle dispersions were removed and the tumors
were washed with PBS. Then, the tumors and the non-pathological CAM were removed from
the eggs, washed again with PBS and spread on a mat black background for observation using
a Maestro II™ in vivo imaging system (Cambridge Research & Instrumentation, Inc., Woburn,
MA). A NIR excitation/emission filter set was used for the experiments (λex: 710–760 nm, λem
> 750 nm). The Liquid Crystal Tunable Filter (LCTF) was programmed to acquire image cubes
from λ = 790 nm to 860 nm with an increment of 10 nm per image. Fluorescence intensity
measurements were calculated as average intensity over the tumor surface area, using ImageJ
software.
7.9.3. In vivo optical detection of human colon tumors in a CAM model
LS174t and SW480 colorectal cell lines were used to demonstrate the possible use of the NIR
fluorescent Prot8 particles in tumor detection. As mentioned before, LS174t cells express
certain receptors (β-D-galactosyl-(1-3)-N-acetyl-D-galactosamine and CEA) at a much higher
extent than SW480 cells [62,65,66]. This way, the chosen bioactive ligands PNA and anti-CEA,
once conjugated to the Prot8 particles, can lead the particles specifically to the LS174t cancer
cells. As shown in Figure 15, the LS174t tumors treated with bioactive-conjugated particles (B
and C) gained higher fluorescence than SW480 tumors, compared to those treated with non-
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conjugated particles (A). This is accurate both for Prot8 particles conjugates with PNA (B) and
anti-CEA (C), probably as a result of effective ligand-receptor interactions. In addition, the
SW480 tumors treated with bioactive-conjugated Prot8 particles gained less fluorescence
compared to those treated with the non-conjugated particles. The relative fluorescence
intensities of the treated tumors by the conjugated and non-conjugated Prot8 particles are
summarized in Figure 16. LS174t cells compared to SW480 cells gave fluorescence intensity
ratios of 4:1 and 8:1 for PNA-conjugated particles and anti-CEA-conjugated particles, respec‐
tively. The non-conjugated Prot8 particles also labeled the tumors, however, the difference in
the intensities between the types of tumors were not statistically significant. In this case, the
overall fluorescence in both types of cells was higher than when treated with PNA-conjugated
particles. This fact shows that even the bare non-conjugated particles penetrate the human
cancer cell lines with a good extent. The possible reason is that the Prot8 particles can penetrate
and label the cancerous cells specifically by either receptor-ligand interaction or utilization of
these particles as nutrients for tumor growth, as they resemble biological proteins. The
fluorescence intensity ratios between the types of cells show the significance of the nanoparticle
surface. As seen in Figure 15D, no autofluorescence was observed in untreated tumors,
signifying that all fluorescent signals are related to the fluorescent Prot8 particles labelling.
Figure 15E shows that no non-specific labelling of non-pathological CAM tissue was observed,
indicating the specificity of the Prot8 particles towards the tumor tissue.
Figure 15. Fluorescent (upper) and greyscale (lower) images from a typical experiment of tumor cell lines LS174t and
SW480 implants on chicken embryo CAM treated with non-conjugated (A), PNA-conjugated (B) and anti-CEA-conju‐
gated (C) NIR fluorescent Prot8 particles. Images of untreated tumor cell lines are shown in (D). Images of non-patho‐
logical CAM treated with non-conjugated, PNA-conjugated and anti-CEA-conjugated particles are shown in (E). The
experiment was repeated 5 times with similar results.
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Figure 16. Relative fluorescence intensities of LS274t and SW480 tumors labeled with non-conjugated, PNA-conjugated
and anti-CEA-conjugated particles. Data is presented as the mean value ± SE. Values not sharing a common letter (a, b,
c or d) differ significantly from each other (p<0.05). The calculations are an average of 3 experiments.
In another set of in vivo experiments on LS174t and SW480 tumors implanted on the CAM
model, the specific biomarker anti-CEA was tested against anti-rabbit IgG, serving as a non-
specific agent, as well as a control group of non-conjugated particles. As clearly illustrated in
Figure 17, LS174t tumors treated with anti-CEA-conjugated particles (B) gained greater
fluorescence compared to those treated with non-conjugated particles (A) or anti-rabbit IgG-
conjugated particles (C). This can be explained by the effective ligand-receptor interaction.
Furthermore, the SW480 tumors treated with the anti-CEA-conjugated particles gained less
fluorescence (about 3.5 times) compared to the LS174t tumors treated the same way. The
fluorescent signal of LS174t tumors labeled by anti-CEA-conjugated particles was 4 times
higher than that of the the tumors labeled by the anti-rabbit IgG-conjugated particles. Anti-
rabbit IgG "blocks" the particle from interacting with the tumor receptors by the conjugation
to the surface active moieties, thus serving as a negative control in colon tumor labelling.
Figure 17. Fluorescent and grayscale images from a typical experiment of LS174t and SW480 human tumor cell lines
implanted on chicken embryo CAM treated with the non-conjugated (A), anti-CEA-conjugated (B) and anti-rabbit IgG-
conjugated (C) NIR fluorescent Prot8 particles. Images of untreated tumors are shown in (D). The experiment was re‐
peated 3 times with similar results.
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7.10. Optical detection of human colon tumors in a mouse model
Experiments were performed according to the protocols of the Israeli National Council for
Animal Experiments by Harlan Biotech, Israel. Cancerous cells (30 µL containing 2×106 LS174t
cells) were injected into the mouse intestinal wall. 2 weeks later the nude mice were anaes‐
thetized and treated with the bio-conjugated NIR fluorescent Prot8 particles (0.1%, 200 µL),
through the anus, using the guidance of a mini-colonoscope. 20 min later each colon was
washed with PBS (5 × 1 mL) and mice were allowed to recover for 4 h. The mice were sacrificed
and the colons were removed. Each colon was spread on a solid surface and imaging was
performed using the Odysey Infra-red Imaging System (Li-Cor Biosciences, Lincoln, NE, USA)
with excitation wavelength of 780 nm and emission wavelength of 800 nm.
Figure 18 shows typical (8 out of 10 mice) fluorescent and grayscale images of the mice colons
after treatment with anti- CEA (A) and anti-rabbit IgG (B) conjugated particles. As illustrated
in Figure 18A, the anti-CEA-conjugated particles detected the tumors specifically and selec‐
tively with good signal to background ratio (SBR), the background refers to the surrounding
non-pathological tissue. Moreover, as illustrated in Figure 18B, the "inactive" anti-rabbit IgG-
conjugated particles did not produce a significant signal of the tumors.
Figure 18. Fluorescent and grayscale images of typical LS174t colon tumors treated with anti-CEA (A) and anti-rabbit
IgG (B)-conjugated NIR fluorescent Prot8 particles. 20 mice (10 in each experiment group) were anesthetized and treat‐
ed with 0.1% particle dispersion in PBS, as described in section 3.2.5.14. 2 untreated mice served as a control group.
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8. Summary and conclusions
In the present study, new proteinoids were prepared using L-glutamic acid, L-aspartic acid,
L-phenylalanine, L-lysine and low molecular weight poly(L-lactic acid). The polymerization
was carried out by a simple straight-forward condensation polymerization in heat. The optimal
conditions for the polymerization were tested, including changing the temperature and using
microwave radiation. The proteinoids made are of high molecular weights with narrow size
distributions and possess optical activity, which can be later used in specific drug delivery
using chirality. The proteinoids are thermally stable and each proteinoid has enough carbox‐
ylic acid and/or amine functional groups, which can be later used to bind covalently desired
molecules, such as drugs and dyes. The incorporation of 2000 Da PLLA into the proteinoid
backbone presented a stable proteinoid as well. Proteinoids were manipulated in several ways
to give proteinoid sphere-shaped nano/micro-particles, and to optimize this process. Specific
conditions were found for the production of hollow particles of narrow size distribution. The
incorporation of PLLA segments into the proteinoids increased the hydrophobic interior part
and resulted in smaller size hollow particles. The particles were found to be non-toxic and
stable over time. Also, encapsulation of different materials was carried out, giving organic-
filled particles and fluorescent particles. In summary, proteinoid formation and cytotoxicity
tests indicate that these particles are suitable for further in vivo testing.
The copolymer Prot8 containing 10% PLLA, was chosen to be used for the biomedical study,
since it provided the smallest particles with the biodegradability derived from the addition of
PLLA to the proteinoid backbone. The proteinoid-PLLA copolymer was self-assembled in the
presence of the NIR fluorescent dye ICG to yield NIR fluorescent Prot8 particles of 70 ± 15 nm
dry diameter. These new NIR fluorescent particles were found to be stable, avoiding leakage
and photobleaching of the NIR dye over time. Furthermore, these particles are non-toxic, as
shown by LDH and XTT assays for cytotoxicity and cell viability on human colorectal
adenocarcinoma cell lines. The particles biodistribution in a mouse model was tested, follow‐
ing an i.v. injection, and the results showed that the particles penetrate a variety of organs,
including the brain and bones. Nevertheless, 1 h post injection, the particles concentrate at
specific sites of the body and are evacuated almost completely over 24 h. It was established,
using the chicken embryo CAM model and the tumor-implanted mouse model, that the NIR
fluorescent particles may be very useful for tumor diagnosis in vivo due to their low auto‐
fluoresence of the background and the deep penetration into biomatrices. In the CAM model,
when the NIR fluorescent proteinoid-PLLA particles are conjugated to a bioactive ligand (PNA
or anti-CEA), they preserve their activity and specifically detect the cancer cells with upregu‐
lated receptors (LS174t vs. SW480). Non-conjugated and anti-rabbit IgG-conjugated NIR
fluorescent particles (control particles) marked the cells without specific recognition at a much
lower fluorescence intensity. In the mouse model, human tumor cells were implanted in mice
colons, and the mice were treated with the NIR fluorescent particles. The results showed that
the anti-CEA-conjugated particles specifically label the colon tumors, as opposed to those
conjugated with anti-rabbit IgG antibodies.
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In summary, the chapter introduced a new series of newly-made proteinoids of a narrow
selection of amino acid monomers, with high molecular weight and very narrow polydisper‐
sity index. Furthermore, this chapter has described proteinoid fluorescent particles as potential
probes for precancerous colorectal adenomatous polyps or colon cancer tumors. Selective and
specific fluorescent labelling of tumors is possible, with very low background signal, however
improvements are still necessary for optimizing the targeting efficiency of the particles. Recent
and ongoing developments in fluorescence imaging systems will open up the scope for
effective detection of fluorescently labelled neoplasm. The proteinoid particles may further be
developed to serve for both diagnostics and therapy combined.
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